Dutasteride: More Than a DHT Reducer – A Potential Androgen Receptor Inhibitor? Finasteride/Dutasteride 12/20/2024
Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity If we lose hair because of our sensitivity to DHT, then why are we trying to reduce DHT when our sensitive androgen receptors are the culprit?
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.
community Having androgen receptor density and sensitivity at wrong f*ing place
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.
community Why some people experience problems on Finasteride/Dutasteride (my theory)
Some people have side effects from finasteride and dutasteride due to hormonal predisposition, especially if DHT dominant. Alternatives like RU58841, Pyrilutamide, and Breezula are suggested to target scalp androgen receptors without altering overall hormones.
community My understanding of how androgenetic alopecia works (plus FIN and DUT)
Androgenetic alopecia is affected by scalp DHT levels, not sensitivity, with treatments like finasteride and dutasteride aiming to optimize these levels. Personalized DHT management is crucial for effective hair growth.
community Testosterone's Role In Androgenetic Alopecia
DHT is essential for androgenetic alopecia, not testosterone. Treatments like finasteride and dutasteride reduce DHT, halting hair loss.
Related Research
6 / 6 results
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
This study reviews the effectiveness and safety of finasteride and dutasteride for treating androgenetic alopecia, highlighting that dutasteride reduces DHT more deeply than finasteride, with genetic factors influencing patient response and both drugs being evidence-supported options for men and women.
research Pharmacological inhibition of 5α-reductase in androgenetic alopecia: a comparative narrative review of finasteride and dutasteride, with attention to responder heterogeneity and female pattern hair loss
This review concludes that finasteride and dutasteride are the most evidence-supported oral treatments for androgenetic alopecia, with dutasteride offering slightly greater hair count improvements and both affected by genetic response modifiers.
research Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases
This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.
research Updates in Treatment for Androgenetic Alopecia
This review discusses current and emerging treatments for androgenetic alopecia, covering mechanisms, efficacy, and safety of both androgen-targeted and non-androgen-targeted approaches, but reports no new clinical results.
research The inflammatory component of androgenetic alopecia
This article discusses hormonal mechanisms underlying androgenetic alopecia but does not report any new findings; it reviews the roles of dihydrotestosterone and available FDA-approved treatments.
research 5α-reductase Inhibitors: Finasteride and Dutasteride in Feminising Therapy
This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.